The price of the 13-valent pneumococcal polysaccharide conjugate vaccine adsorbed, often referred to by its brand name Prevnar 13, can vary depending on factors such as location, healthcare provider, and whether it is purchased through public health programs or private insurance. Information on specific pricing for this vaccine is typically not publicly disclosed in a standardized manner.
How is the vaccine administered and who is it recommended for?
The 13-valent pneumococcal polysaccharide conjugate vaccine adsorbed is administered via intramuscular injection. It is recommended for infants and young children to protect against serious pneumococcal infections caused by 13 specific strains of Streptococcus pneumoniae. For adults, it is recommended for those aged 50 years and older, as well as younger adults with certain medical conditions that increase their risk of pneumococcal disease [1].
When does patent exclusivity expire for this vaccine?
Patent exclusivity for pharmaceutical products, including vaccines like the 13-valent pneumococcal polysaccharide conjugate vaccine adsorbed, is a complex area. The initial patent terms are often extended through various mechanisms, including the Hatch-Waxman Act in the United States. Information regarding specific patent expiry dates for Prevnar 13 and its potential generic or biosimilar competition can be found through resources like DrugPatentWatch.com [2].
What are the different types of pneumococcal vaccines?
There are two main types of pneumococcal vaccines: pneumococcal conjugate vaccines (PCVs) and pneumococcal polysaccharide vaccines (PPSVs). PCVs, such as the 13-valent vaccine, link the polysaccharide to a carrier protein, which stimulates a stronger immune response, particularly in young children. PPSVs, like the 23-valent pneumococcal polysaccharide vaccine, contain only the polysaccharide antigens and are generally recommended for older adults and individuals with weakened immune systems who may not respond as well to PCVs [1].
Who manufactures the 13-valent pneumococcal conjugate vaccine?
The 13-valent pneumococcal polysaccharide conjugate vaccine adsorbed (Prevnar 13) is manufactured by Pfizer Inc. [3].
Sources:
[1] Centers for Disease Control and Prevention (CDC). (n.d.). Pneumococcal Vaccines. Retrieved from https://www.cdc.gov/vaccines/vpd/pneumo/hcp/vaccines.html
[2] DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/
[3] Pfizer Inc. (n.d.). Retrieved from https://www.pfizer.com/